nephrology

News

AstraZeneca has staked a claim to the increasingly crowded IgAN market with an accelerated approval from the FDA for Ultomiris, its fifth indication.

R&D

Purespring CEO Haseeb Ahmad discusses transforming the treatment of kidney disease, an area of enormous unmet need, and the company's gene therapy.

News

AstraZeneca has returned to China's CSPC Pharma to fill its R&D pipeline, reaching a new $1.77bn agreement to develop drugs for kidney diseases.

News

Unicycive Therapeutics' hopes of getting FDA approval of its drug for hyperphosphataemia in dialysis patients have been knocked back again.

News

Shrugging off an earlier phase 3 disappointment, Travere’s Filspari has become the first FDA-approved treatment for rare kidney disease FSGS.

News

Bayer's Kerendia has hit the spot in another phase 3 trial that could fuel its already rapid growth as a chronic kidney disease treatment.